Oxidative damage and Alzheimer's disease: Are antioxidant therapies useful?

Drug News and Perspectives

Volumn 18, Issue 1, 2005, Pages 13-19

  Moreira, Paula I ^a,b   Smith, Mark A ^a   Zhu, Xiongwei ^a   Honda, Kazuhiro ^a   Lee, Hyoung Gon ^a   Aliev, Gjumrakch ^a   Perry, George ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ASCORBIC ACID; BETA CAROTENE; CARBOHYDRATE; FLAVONOID; FREE RADICAL; GINKGO BILOBA EXTRACT; LIPID; NUCLEIC ACID; PROTEIN;

ADAPTATION; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; HUMAN; NERVE INJURY; NEUROFIBRILLARY TANGLE; OXIDATIVE STRESS; PATHOGENESIS; REVIEW;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; HUMANS; OXIDATIVE STRESS;

EID: 17444377148     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2005.18.1.877165     Document Type: Review

References (71)

1. Khachaturian, Z.S. Diagnosis of Alzheimer's disease. Arch Neurol 1985, 42: 1097-105.
2. Mirra, S.S., Heyman, A., McKeel, D. et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41: 479-86.
3. Smith, M.A., Harris, P.L., Sayre, L.M. and Perry, G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997, 94: 9866-8.
4. Smith, M.A., Harris, P.L.R., Sayre, L.M., Beckman, J.S. and Perry, G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997, 17: 2653-7.
5. Davis, R.E., Miller, S., Hermstadt, C. et al. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci USA 1997, 94: 4526-31.
6. Sorbi, S., Bird, E.D., Blass, J.P. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol 1983, 13: 72-8.
7. Blass, J.P., Sheu, R.K. and Gibson, G.E. Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Ann NY Acad Sci 2000, 903: 204-21.
8. Aliev, G., Seyidova, D., Neal, M.L. et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann NY Acad Sci 2002, 977: 45-64.
9. Smith, M.A., Nunomura, A., Zhu, X., Takeda, A. and Perry, G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antiox Redox Signal 2000, 2: 413-20.
10. Hirai, K., Aliev, G., Nunomura, A. et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001, 21: 3017-23.
11. Castellani, R., Hirai, K., Aliev, G. et al. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 2002, 70: 357-60.
12. Cash, A.D., Aliev, G., Siedlak, S.L. et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 2003, 162: 1623-7.
13. Nunomura, A., Perry, G., Hirai, K. et al. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann NY Acad Sci 1999, 893: 362-4.
14. Nunomura, A., Perry, G., Pappolla, M.A. et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 1999, 19: 1959-64.
15. Smith, M.A., Wehr, K., Harris, P.L., Siedlak, S.L., Connor, J.R. and Perry, G. Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res 1998, 788: 232-6.
16. Perry, G., Sayre, L.M., Atwood, C.S. et al. The role of iron and copper in the aetiology of neurodegenerative disorders: Therapeutic implications. CNS Drugs 2002, 16: 339-52.
17. Lovell, M.A., Robertson, J.D., Teesdale, W.J., Campbell, J.L. and Markesbery, W.R. Copper, iron and zinc in Alzheimer's disease senile plagues. J Neurol Sci 1998, 158: 47-52.
18. Perez, M., Valpuesta, J.M., de Garcini, E.M. et al. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. Am J Pathol 1998, 152: 1531-9.
19. Nunomura, A., Perry, G., Pappola, M.A. et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 2000, 59: 1011-7.
20. Nunomura, A., Perry, G., Aliev, G. et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001, 60: 759-67.
21. Smith, M.A., Perry, G., Richey, P.L. et al. Oxidative damage in Alzheimer's. Nature 1996, 382: 120-1.
22. Cras, P., Smith, M.A., Richey, P.L., Siedlak, S.L., Mulvihill, P. and Perry, G. Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol (Berl) 1995, 89: 291-5.
23. Smith, M.A., Siedlak, S.L., Richey, P.L., Nagaraj, R.H., Elhammer, A. and Perry, G. Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease. Brain Res 1996, 717: 99-108.
24. Sayre, L.M., Zelasko, D.A., Harris, P.L.R., Perry, G., Salomon, R.G. and Smith, M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997, 68: 2092-7.
25. Smith, M.A., Taneda, S., Richey, P.. et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sc USA 1994, 91: 5710-4.
26. Smith, M.A., Rudnicka-Nawrot, M., Richey, P.L. et al. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem 1995, 64: 2660-6.
27. Castellani, R.J., Harris, P.L., Sayre, L.M. et al. Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med 2001, 31: 175-80.
28. Perry, G., Taddeo, M.A., Nunomura, A. et al. Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: Beyond damage and response. Comp Biochem Physiol C Toxicol Pharmacol 2002, 133: 507-13.
29. Unnikrishnan, M.K. and Rao, M.N. Antiinflammatory activity of methionine, methionine sulfoxide and methionine sulfone. Agents Actions 1990, 31: 110-2.
30. Hiller, K.O. and Asmus, K.D. Tl2+ and Ag2+ metal-ion-induced oxidation of methionine in aqueous solution. A pulse radiolysis study. Int J Radiat Biol Relat Stud Phys Chem Med 1981, 40: 597-604.
31. Cadenas, E. and Davies, K.J. Mitochondrial free radical generation, oxidative stress and aging. Free Rad Biol Med 2000, 29: 222-30.
32. Iversen, L.L., Mortishire-Smith, R.J., Pollack, S.J. and Shearman, M.S. The toxicity in vitro of beta-amyloid protein. Biochem J 1995, 311: 1-16.
33. Kontush, A. Amyloid-beta: An antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic Biol Med 2001, 31: 1120-31.
34. Schubert, D. and Chevion, M. The role of iron in beta amyloid toxicity. Biochem Biophys Res Commun 1995, 233: 760-4.
35. Bondy, S.C., Guo-Ross, S.X. and Truong, A.T. Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res 1998, 799: 91-6.
36. Rottkamp, C.A., Raina, A.K., Zhu, X. et al. Redox-active iron mediated amyloid-beta toxicity. Free Radic Biol Med 2001, 30: 447-50.
37. Huang, X., Atwood, C.S., Hartshorn, M.A. et al. The Abeta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999, 38: 7609-16.
38. Walter, M.F., Mason, P.E. and Mason, R.P. Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions. Biochem Biophys Res Commun 1997, 233: 760-4.
39. Varadarajan, S., Yatin, S., Aksenova, M. and Butterfield, D.A. Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 2000, 130: 184-208.
40. Butterfield, D.A. and Bush, A.I. Alzheimer's amyloid beta-peptide (1-42): Involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging 2004, 25: 563-8.
41. Soriani, M., Pietraforte, D. and Minetti, M. Antioxidant potential of anaerobic human plasma: Role of serum albumin and thiols as scavengers of carbon radicals. Arch Biochem Biophys 1994, 312: 180-8.
42. Lynch, S.M. and Frei, B. Physiological thiol compounds exert pro- and anti-oxidant effects, respectively, on iron- and copper-dependent oxidation of human low-density lipoprotein. Biochem Biophys Res Commun 1997, 186: 944-50.
43. Buée, L., Bussiere, T., Buée-Scherrer, V., Delacourte, A. and Hof, P.R. Tau isoforms in neurodegenerative disorders. Brain Res Rev 2000, 33: 95-130.
44. Brandt, R., Leger, J. and Lee, G. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol 1995, 131: 1327-40.
45. Sontag, E., Nunbhakdi-Craig, V., Lee, G. et al. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem 1999, 274: 25490-8.
46. Hamdane, M., Delobel, P., Sambo, A.-V. et al. Neurofibrillary degeneration of the Alzheimer-type: An alternate pathway to neuronal apoptosis? Biochem Pharmacol 2003, 66: 1619-25.
47. Garcia, M.L. and Cleveland, D.W. Going new places using an old MAP: Tau, microtubules and human neurodegenerative disease. Curr Opin Cell Biol 2001, 13: 41-8.
48. Takeda, A., Smith, M.A., Avila, J. et al. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J Neurochem 2000, 75: 1234-41.
49. Morsch, R., Simon, W. and Coleman, P.D. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 1999, 58: 188-97.
50. Wataya, T., Nunomura, A., Smith, M.A. et al. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 2002, 277: 4644-8.
51. Zhu, X., Rottkamp, C.A., Boux, H., Takeda, A., Perry, G. and Smith, M.A. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 2000, 59: 880-8.
52. Zhu, X., Raina, A.K., Rottkamp, C.A., Aliev, G., Perry, G., Boux, H. and Smith, M.A. Activation and redistribution of the c-Jun N-terminal kinase/stress activated protein kinase in degeneration neurons in Alzheimer's disease. J Neurochem 2001, 76: 435-41.
53. Zhu, X., Rottkamp, C.A., Hartzier, A. et al. Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J Neurochem 2001, 79: 311-8.
54. Monsonego, A. and Weiner, H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 2003, 302: 834-8.
55. Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H. and Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med 2003, 9: 448-52.
56. Pratico, D. and Delanty, N. Oxidative injury in disease of the central nervous system: Focus on Alzheimer's disease. Am J Med 2000, 109: 577-85.
57. Rottkamp, C.A., Nunomura, A., Hirai, K., Sayre, L.M., Perry, G. and Smith, M.A. Will antioxidants fulfill their expectations for the treatment of Alzheimer disease? Mech Aging Develop 2000, 116: 169-79.
58. Rutten, B.P., Steinbusch, H.W., Korr, H. and Schmitz, C. Antioxidants and Alzheimer's disease: From bench to bedside (and back again). Curr Opin Clin Nutr Metab Care 2002, 5: 645-51.
59. Delanty, N. and Dichter, M.A. Antioxidant therapy in neurologic disease. Arch Neurol 2000, 57: 1265-70.
60. Polidori, M.C., Mattioli, P., Aldred, S. et al. Plasma antioxidant status, immunoglobulin G oxidation and lipid peroxidation in demented patients: Relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord 2004, 18: 265-70.
61. Sano, M., Ernesto, C., Thomas, R.G. et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997, 336: 1216-22.
62. Engelhart, M.J., Geerlings, M.I., Ruitenberg, A. et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002, 287: 3223-9.
63. Zandi, P.P., Anthony, J.C., Khachaturian, A.S. et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol 2004, 61: 82-8.
64. Laurin, D., Masaki, K.H., Foley, D.J., White, L.R. and Launer, L.J. Midlife dietary intake of antioxidants and risk of late-life incident dementia: The Honolulu-Asia Aging Study. Am J Epidemiol 2004, 159: 959-67.
65. Packer, L., Tritschler, H.J. and Wessel, K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997, 22: 359-78.
66. Hagen, T.M., Ingersoll, R.T., Lykkesfeldt, J. et al. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J 1999, 13: 411-8.
67. Suh, J.H., Wang, H., Liu, R.M., Liu, J. and Hagen, T.M. (R)-alpha-lipoic acid reverses the age-related loss in GSH redox status in post-mitotic tissues: Evidence for increased cystetne requirement for GSH synthesis. Arch Biochem Biophys 2004, 423: 126-35.
68. Frolich, L., Gotz, M.E., Weinmuller, M. et al. (r)-, but not (s)-alpha lipoic acid stimulates deficient brain pyruvate dehydrogenase complex in vascular dementia, but not in Alzheimer dementia. J Neural Transm 2004, 111: 295-310.
69. Stackman, R.W., Eckenstein, F., Frei, B., Kulhanek, D., Nowlin, J. and Quinn, J.F. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol 2003, 184: 510-20.
70. Colciaghi, F., Borroni, B., Zimmermann, M. et al. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis 2004, 16: 454-60.
71. Le Bars, P.L., Katz, M.M., Herman, N., Itil, T.M., Freedman, A.M. and Schatzberg, A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997, 278: 1327-32.